Pozen plots tax inversion with $144M Tribute buy; Lilly eyes Q3 European launch for Lantus biosim;

@FiercePharma: Are European investors catching on to the value of animal health? FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA warning letter says Czech company shipped bacteria contaminated APIs to the U.S. Article | Follow @EricPFierce

@CarlyHFierce: U.K. cost watchdogs boost J&J's Stelara ahead of hefty competition. More | Follow @CarlyHFierce

> A week after it brought in new managers to replace founder and CEO John Plachetka, Pozen says it's doing a tax inversion deal with the $144 million buyout of Tribute Pharmaceuticals Canada, moving its official domicile to Ireland. Report

> Eli Lilly & Co.'s ($LLY) diabetes chief, Enrique Conterno, said it plans to roll out its version of Sanofi's ($SNY) blockbuster basal insulin Lantus in Europe in the third quarter. Report

> Bayer's radio-oncology med Xofigo won backing from England's National Institute for Health and Care Excellence as a treatment for prostate cancer. Report

> Cardinal Health plans to buy the generic drug distributor Harvard Drug Group for $1.12 billion to extend its reach in generics and over-the-counter meds. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Medtronic aims for diabetic consumer tech in deals with Samsung, Glooko and connected MiniMed clearance. Article | Follow @FierceMedDev

@VarunSaxena2: 'Heart in a Box' for preserving transplanted organs received $20M in funding. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: NICE sings a different tune for Bayer's prostate cancer drug Xofigo. Story | Follow @EmilyWFierce

> Medtronic touts data in support of FDA approval of the latest MiniMed glucose monitor. Story

> Alibaba founder pumps $142M into Beijing-based devicemaker. Article

Biotech News

@FierceBiotech: Novo Nordisk's diabetes combo beats Lantus in Phase III. Report | Follow @FierceBiotech

@JohnCFierce: UPDATED: Patriots owner Kraft teams up on a $30M antibiotics A round for Spero. News | Follow @JohnCFierce

@DamianFierce: $TEVA chief Erez Vigodman signs his letters to $MYL with initials only, such is his commitment to synergies. | Follow @DamianFierce

> FDA asks experts to weigh in on PCSK9 drugs' market reach for Amgen, Regeneron/Sanofi. Report

> Buzz: Sobi spurns Pfizer's rumored $5B buyout deal. More

Animal Health News

> USDA says deadly avian flu virus on the wane in the Midwest as weather warms. Report

> Nexvet shares rebound on positive data from study of pain drug in cats. Item

> FDA launches safety investigation of controversial raw foods for pets. More

> Cancer immunotherapy tried in pet dogs moves to human trials. Story

> Eli Lilly, Zoetis among stakeholders signing on to White House antibiotics plan. Article

Biotech IT News

> Amazon, Google duke it out for control of cloud genomics. Story

> 10X Genomics poaches David Jaffe from the Broad Institute. Item

> U.K. overrun by requests to opt-out of health data sharing program. Article

> Saama raises $35M to fuel push into life science data analytics. News

> Illumina misses out as U.K. picks interpretation providers for 100K Genomes Project. Report

Pharma Marketing News

> ADA highlights: Novo, Lilly meds top Lantus; Sanofi, AZ tout new combo regimens. More

> Pfizer apologizes to U.K. docs as Lyrica protection campaign hits snag. Report

> AbbVie, J&J gallop toward first-line Imbruvica sales with new survival data. Story

> Never too old to be young, Pfizer says, with new tack on Get Old campaign. Article

> Five digital campaigns that show pharma really can do it. Feature

And Finally... Companies are adopting tech-oriented apps and programs to help fend off diabetes in their employees. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.